The latter corresponds to a 23% loss of AF prevention by SGLT2 inhibitors (i.e. 23% increase in the RR of AF in the SGLT2 inhibitor arm compared with placebo) for every 10% increase in the mean LVEF of the patients included in the RCT. The gene discussed is SLC5A2; the disease is atrial fibrillation.